Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models

[摘要] With 5-year survival rates below 5%, small cell lung carcinoma (SCLC) has very poor prognosis and requires improved therapies. Despite an excellent overall response to first-line therapy, relapses are frequent and further treatments are disappointing. The

[学科分类] 呼吸医学